StockData
Anebulo Pharmaceuticals, Inc. logo

Anebulo Pharmaceuticals, Inc. (ANEB) stock

ANEBNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q2 FY2026, quarter ended Dec 31, 2025Last filing: 10-Q on Feb 12, 2026Score 0/30
$0.00+0.00 (+75.00%)

Close on Oct 19, 2026Market cap $28.76KP/E –Yield –

Anebulo Pharmaceuticals statistics

20 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings
–
Last ex-dividend date
No dividends
Fundamentals through
Dec 31, 2025
Share price as of
–

Share statisticsIndustry

Shares Change (YoY)
56.2%
10.8%
Shares Change (QoQ)
0.00%
0.50%

Returns on capitalIndustry

Return on Equity (ROE)
-69.7%
-49.9%
Return on Assets (ROA)
-63.2%
-40.6%

Financial positionIndustry

Interest Coverage
-20.98
-6.35

EfficiencyIndustry

Profits Per Employee
-$3.99M
-$689.41K
Employee Count
2
74

Income statement (TTM)Industry

Operating Income
-$9.10M
-$21.37M
Net Income
-$7.98M
-$22.35M
EBITDA
-$9.10M
-$17.21M
EPS (Diluted)
-$0.19
-$0.76

Balance sheetIndustry

Net Cash (Debt)
$9.04M
$17.76M
Net Cash Per Share
$0.22
$0.80
Equity (Book Value)
$7.94M
$53.89M
Book Value Per Share
$0.19
$1.50
Tangible Book Value
$7.94M
$27.13M

Cash flow (TTM)Industry

Operating Cash Flow
-$5.84M
-$12.38M

Taxes and interestIndustry

Interest Expense
$434.00K
$2.90M

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.

PeriodANEBS&P 500DifferenceANEB per yearS&P 500 per year
1 month-99.8%+0.6%−100.4 pts
3 months-99.8%+3.4%−103.2 pts
Year to date-99.9%+13.3%−113.2 pts
1 year-100.0%+16.6%−116.6 pts
3 years-100.0%+86.4%−186.4 pts-93.8%+23.1%
5 years-100.0%+81.9%−181.8 pts-84.3%+12.7%

Short interest

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

0M ANEB shares were sold short on Oct 30, 2026, up 0.0% from the previous report. At recent volumes it would take 1000.0 days to buy them back. Over the last 20 sessions, 47.4% of the volume reported to FINRA was short selling.

Settlement dateShares shortChangeAvg. daily volumeDays to cover
Oct 30, 2026390,8080.0%3631000.0
Oct 15, 2026390,8080.0%1861000.0
Sep 30, 2026390,808-0.0%624626.3
Sep 15, 2026390,985+6838.5%2201000.0
Aug 31, 20265,6350.0%18430.6
Aug 14, 20265,6350.0%54010.4
Jul 31, 20265,6350.0%9076.2
Jul 15, 20265,635+0.2%6448.8
Jun 30, 20265,623-0.5%2,3672.4
Jun 15, 20265,649-1.8%10,3241.0
May 29, 20265,7520.0%10,0741.0
May 15, 20265,7520.0%4,4731.3

Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.

See a number that looks wrong?